Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...

Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Australia's corporate regulator said on Tuesday the country's stock market operator would be required to publish a comparison ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...

Coreline Soft, a medical AI specialist, will participate in the European Congress of Radiology (ECR) 2025, held at the Austria Center Vienna from February 26 to March 2. ECR is Europe's largest ...

Indivior PLC , a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid initiation protocol ...